查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
病毒載體和質粒DNA製造的全球市場：按類型(病毒載體、質粒DNA)、工作流程、應用、適應症和最終用戶劃分的未來預測(至2028年)
市場調查報告書
商品編碼
1295434

病毒載體和質粒DNA製造的全球市場：按類型(病毒載體、質粒DNA)、工作流程、應用、適應症和最終用戶劃分的未來預測(至2028年)

Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector, Plasmid DNA), Workflow, Application, Diseases, End User - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 317 Pages | 訂單完成後即時交付

價格
簡介目錄

全球病毒載體和質粒DNA製造市場規模將從2023年的55億美元增至2028年的128億美元，預計複合年增長率為18.2%。

該市場的增長得益於基因療法開發融資的可用性。 基因治療是一個快速發展的領域，需要研發、臨床試驗和製造資金。 例如，2022年12月，生物技術公司SonoThera宣布完成6075萬美元A輪融資。 這筆資金將支持 SonoThera 超聲引導的非病毒基因治療平台和旨在為患者提供基因藥物的療法的持續開發。

“在預測期內，載體擴增、編輯和延伸部分將佔上游製造工藝的最大份額”

2022年，載體擴增、編輯和延伸領域在全球病毒載體和質粒DNA製造市場中佔據上游製造工藝的最大份額。 載體擴增、編輯和延伸是病毒載體和質粒 DNA 生產的關鍵步驟，因為它們直接影響載體的數量、質量和功能。 製藥和生物製藥行業取得了重大進展，特別是在新型療法和疫苗的開發方面。 病毒載體和質粒DNA是傳遞治療基因和疫苗抗原的重要工具。 對載體擴增、編輯和延伸的需求是由於需要為不同的治療方法和候選疫苗生產不同的病毒載體和質粒 DNA。

“歐洲：按地區劃分的第二大地區”

歐洲是全球第二大病毒載體和質粒 DNA 製造市場，僅次於北美。 近年來，由於多種因素支持其擴張，歐洲病毒載體/質粒 DNA 製造市場經歷了顯著增長。 歐洲處於病毒載體和質粒 DNA 製造市場新技術開發和採用的前沿。 這包括病毒載體和質粒 DNA 製造技術的進步。 這些創新技術的採用將加速病毒載體/質粒DNA生產研究的進展並擴大應用領域。 此外，在歐洲，我們還提供針對病毒載體和質粒 DNA 製造的全面培訓和教育計劃。 會議由大學、研究機構和組織資助，旨在提高科學家和研究人員的知識和技能。 此類資金促進了病毒載體和質粒 DNA 製造技術在歐洲的採用和使用。

內容

第 1 章簡介

第 2 章研究方法

第 3 章執行摘要

第 4 章重要考慮因素

第 5 章市場概述

  • 簡介
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
  • 參考價格分析
  • 價值鏈分析
  • 價值鏈分析：在製造階段增加最大價值
  • 波特五力分析
  • 技術分析
  • 專利分析
  • 影響客戶業務的趨勢/干擾
  • 監管分析
  • 重大會議和活動（2022-2023）
  • 主要利益相關者和採購標準

第 6 章按類型劃分的病毒載體和質粒 DNA 製造市場

  • 簡介
  • 病毒載體
    • 逆轉錄病毒
    • 腺病毒
    • 腺相關病毒
    • 慢病毒
    • 其他病毒載體
  • 質粒 DNA

第 7 章病毒載體和質粒 DNA 製造市場：按產品/服務

  • 簡介
  • 產品
  • 服務

第 8 章病毒載體和質粒 DNA 製造市場：按工作流程

  • 簡介
  • 上游製造流程
    • 矢量放大/編輯/擴展
    • 載體恢復/收集
  • 下游製造流程
    • 細化
    • 填充和整理

第 9 章病毒載體和質粒 DNA 製造市場：按應用分類

  • 簡介
  • 細胞和基因治療
  • 疫苗開發
  • 研究

第 10 章病毒載體和質粒 DNA 製造市場：按適應症分類

  • 簡介
  • 癌症
  • 遺傳性疾病
  • 感染
  • 其他指示

第 11 章病毒載體和質粒 DNA 製造市場：按最終用戶劃分

  • 簡介
  • 製藥和生物製藥公司
  • 學術研究所
  • 其他最終用戶

第 12 章按地區劃分的病毒載體和質粒 DNA 製造市場

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲

第 13 章競爭格局

  • 簡介
  • 大公司採用的贏者獲勝的方法
  • 市場份額分析
  • 收入份額分析
  • 公司評估矩陣：主要公司
  • 排名前 25 名的公司的競爭基準
  • 公司評估矩陣：初創公司/中小企業
  • 競爭基準：初創企業/中小企業
  • 競爭場景和趨勢

第 14 章公司簡介

  • 主要公司
    • LONZA GROUP
    • MERCK KGAA
    • THERMO FISHER SCIENTIFIC INC.
    • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • CATALENT, INC.
    • WUXI APPTEC CO., LTD.
    • FUJIFILM CORPORATION
    • GENSCRIPT BIOTECH CORPORATION
    • TAKARA BIO INC.
    • OXFORD BIOMEDICA
    • NOVARTIS AG
    • PRECISION BIOSCIENCES
    • BLUEBIRD BIO, INC.
    • SARTORIUS AG
    • DANAHER CORPORATION
    • SIRION BIOTECH
  • 其他公司
    • VGXI, INC.
    • WAISMAN BIOMANUFACTURING
    • KANEKA EUROGENTEC S.A.
    • PLASMIDFACTORY GMBH
    • ATUM
    • ADDGENE
    • CELL AND GENE THERAPY CATAPULT
    • BATAVIA BIOSCIENCES B.V.
    • ALTOGEN BIOSYSTEMS

第 15 章附錄

簡介目錄
Product Code: BT 6497

The global viral vector and plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the availability of funding for the development of gene therapy. Gene therapy is a rapidly growing field, and funding is needed for research and development, clinical trials, and manufacturing. For instance, in December 2022, SonoThera, a biotechnology company announced completion of its USD 60.75 million Series A financing round. The financing will support the continued development of SonoThera's ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.

"The vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process during the forecast period"

In 2022, vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process in the global viral vector and plasmid DNA manufacturing market. Vector amplification, editing, and expansion are critical steps in viral vector and plasmid DNA manufacturing as they directly impact the quantity, quality, and functionality of the vectors. The pharmaceutical and biopharmaceutical industry is witnessing significant advancements, particularly in the development of novel therapeutics and vaccines. Viral vectors and plasmid DNA are crucial tools for delivering therapeutic genes or vaccine antigens. The demand for vector amplification, editing, and expansion is driven by the need to produce a diverse range of viral vectors and plasmid DNA for various therapeutic and vaccine candidates.

"Europe: The second largest region in the viral vector and plasmid DNA manufacturing market"

Europe accounted for the second-largest market for viral vector and plasmid DNA manufacturing market after North America. The European viral vector and plasmid DNA manufacturing market has witnessed significant growth in recent years, driven by various factors that have propelled its expansion. Europe is at the forefront of developing and adopting emerging technologies in the field of viral vector and plasmid DNA manufacturing market. This includes advancements in viral vector and plasmid DNA manufacturing gtechnologies. The adoption of these innovative technologies accelerates the progress of viral vector and plasmid DNA manufacturing research and expands its applications. Additionally, Europe offers comprehensive training and education programs in viral vector and plasmid DNA manufacturing. Universities, research institutes, and organizations provide funding, and conferences to enhance the knowledge and skills of scientists and researchers. The availability of funding promotes the adoption and utilization of of viral vector and plasmid DNA manufacturing technologies in Europe.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: C-level - 45%, D-level - 30%, and Others - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%

List of Companies Profiled in the Report:

  • Lonza Group (Switzerland)
  • Thermo Fisher Scientific Inc. (US)
  • Merck KGaA (Germany)
  • Oxford Biomedica (UK)
  • FUJIFILM Corporation (Japan)
  • Charles River Laboratories International, Inc. (US)
  • Danaher Corporation (US)
  • Genscript Biotech Corporation (US)
  • SIRION BIOTECH (Germany)
  • Catalent, Inc (US)
  • Novartis AG (Switzerland)
  • Precision Biosciences (US)
  • Takara Bio Inc. (japan)
  • Bluebird Bio, Inc. (US)
  • Sartorius AG (Germany)
  • VGXI, INC. (US)
  • Waisman Biomanufacturing (US)
  • Kaneka Eurogentec S.A. (Belgium)
  • PlasmidFactory GmbH (Germany)
  • WuXi AppTec (China)
  • Atum (US)
  • Addgene (US)
  • Cell and Gene Therapy Catapult (US)
  • Batavia Biosciences B.V. (Netherlands)
  • Altogen Biosystems (US)

Research Coverage:

This report provides a detailed picture of the viral vector and plasmid DNA manufacturing market. It aims at estimating the size and future growth potential of the market across different segments such as the type, product & service, workflow, application, disease indication, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges

The report provides insights on the following pointers:

  • Analysis of key drivers (rising prevalence of genetic disorders, cancer, and infectious diseases, availability of funding for the development of gene therapy, effectiveness of viral vectors and ongoing research into viral vector-based gene and cell therapies), restraints (High operational costs associated with cell & gene therapy manufacturing and Short shelf-life of viral vectors), opportunities (Smart capital deployment and planning for scalability, and Leveraging digital to facilitate operational excellence), and challenges (Risk of mutagenesis and other unwanted outcomes, and Individual optimization and low yields hold back downstream processes) influencing the growth of the market.
  • Product and Service Development/Innovation: Detailed insights on newly launched products & services, and technological assessment of the viral vector and plasmid DNA manufacturing market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the viral vector and plasmid DNA manufacturing market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and products and service offerings of leading players like Lonza Group AG (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Charles River Laboratories International, Inc. (US), Catalent Inc. (US), WuXi AppTec (China), FUJIFILM Corporation (Japan), GenScript Biotech Corporation (US), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Novartis AG (Switzerland), Precision Biosciences (US), Bluebird Bio, Inc. (US), Sartorius AG (Germany), Danaher Corporation (US), SIRON Biotech (Germany), VGXI, Inc. (US), Waisman Biomanufacturing (US), Kaneka Eurogentec S.A. (Belgium), PlasmidFactory GmbH (Germany), ATUM (US), Addgene (US), Cell and Gene Therapy Catapult (UK), Batavia biosciences (Netherlands), and Altogen Biosystems (US)., and among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • FIGURE 1 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION
    • 1.3.1 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022
    • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
    • FIGURE 6 ILLUSTRATIVE EXAMPLE OF LONZA GROUP AG: REVENUE SHARE ANALYSIS (2022)
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
    • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH FORECAST
    • FIGURE 9 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: CAGR PROJECTIONS
    • FIGURE 10 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 12 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 17 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 18 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET OVERVIEW
    • FIGURE 19 ONGOING RESEARCH ON VIRAL VECTOR-BASED CELL AND GENE THERAPIES TO DRIVE MARKET
  • 4.2 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: NORTH AMERICA, BY PRODUCT & SERVICE AND COUNTRY
    • FIGURE 20 PRODUCTS SEGMENT IN US ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 21 PRODUCTS SEGMENT TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SHARE, BY END USER (2022)
    • FIGURE 22 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.5 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 23 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 24 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of genetic disorders, cancer, and infectious diseases
      • 5.2.1.2 Availability of funding for development of gene therapy
      • 5.2.1.3 Effectiveness of viral vectors
      • 5.2.1.4 Ongoing research on viral vector-based gene and cell therapies
    • TABLE 5 OVERVIEW OF CURRENT CLINICAL TRIALS BASED ON VECTOR TYPE
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High operational costs associated with cell and gene therapy manufacturing
      • 5.2.2.2 Short shelf life of viral vectors
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Smart capital deployment and planning for scalability
      • 5.2.3.2 Leveraging digital tools to facilitate operational excellence
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Risk of mutagenesis and other unwanted outcomes
      • 5.2.4.2 Individual optimization and low yield
  • 5.3 INDICATIVE PRICING ANALYSIS
    • TABLE 6 PRICING ANALYSIS FOR PRODUCTS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS: MANUFACTURING PHASES ADD MAXIMUM VALUE
    • 5.5.1 ECOSYSTEM ANALYSIS
    • FIGURE 25 ECOSYSTEM ANALYSIS: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET
    • TABLE 7 OVERALL MARKET ECOSYSTEM FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 THREAT OF SUBSTITUTES
    • 5.6.3 BARGAINING POWER OF BUYERS
    • 5.6.4 BARGAINING POWER OF SUPPLIERS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 TECHNOLOGY ANALYSIS
    • TABLE 9 EXAMPLES OF ADVANCED PRODUCTS/PLATFORMS
  • 5.8 PATENT ANALYSIS
    • FIGURE 26 TOP PATENT OWNERS IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, JANUARY 2014 TO JANUARY 2023
    • TABLE 10 EXAMPLES OF RECENT PATENT ACTIVITY IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 27 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURERS
  • 5.10 REGULATORY ANALYSIS
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 15 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 16 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: LIST OF CONFERENCES AND EVENTS
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS
    • 5.12.2 BUYING CRITERIA FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS AND SERVICES
    • FIGURE 29 KEY BUYING CRITERIA FOR END USERS

6 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 17 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2 VIRAL VECTOR
    • TABLE 18 VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 19 VIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 NORTH AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 LATIN AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.1 RETROVIRUS
      • 6.2.1.1 Rising application of retroviruses in gene therapy and gene transfer studies to support growth
    • TABLE 24 RETROVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 25 NORTH AMERICA: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 EUROPE: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 28 LATIN AMERICA: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.2 ADENOVIRUS
      • 6.2.2.1 Large capacity for carrying genetic material to promote growth
    • TABLE 29 ADENOVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 30 NORTH AMERICA: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 EUROPE: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 LATIN AMERICA: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.3 ADENO-ASSOCIATED VIRUS
      • 6.2.3.1 Low toxicity to support demand growth
    • TABLE 34 AAV VECTOR MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 35 NORTH AMERICA: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 EUROPE: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 LATIN AMERICA: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.4 LENTIVIRUS
      • 6.2.4.1 Ability to infect both dividing and non-dividing cells to drive growth
    • TABLE 39 LENTIVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 EUROPE: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 LATIN AMERICA: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.5 OTHER VIRAL VECTORS
    • TABLE 44 OTHER VIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 LATIN AMERICA: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 PLASMID DNA
    • 6.3.1 GROWING R&D AND LAUNCHES OF PRODUCTION PLATFORMS TO BOOST MARKET
    • TABLE 49 PLASMID DNA MANUFACTURING MARKET, BY REGION 2021-2028 (USD MILLION)
    • TABLE 50 NORTH AMERICA: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 EUROPE: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 ASIA PACIFIC: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 LATIN AMERICA: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE

  • 7.1 INTRODUCTION
    • TABLE 54 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • 7.2 PRODUCTS
    • 7.2.1 INCREASING PRODUCT LAUNCHES TO DRIVE MARKET GROWTH
    • TABLE 55 VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS, BY KEY PLAYER
    • TABLE 56 VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 SERVICES
    • 7.3.1 INCREASING DEMAND FOR SERVICES TO BOOST MARKET
    • TABLE 61 VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES, BY KEY PLAYER
    • TABLE 62 VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 66 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW

  • 8.1 INTRODUCTION
    • TABLE 67 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
  • 8.2 UPSTREAM MANUFACTURING
    • TABLE 68 VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 69 VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 70 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 71 EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.1 VECTOR AMPLIFICATION, EDITING, AND EXPANSION
      • 8.2.1.1 Increasing demand for gene therapy to fuel growth
    • TABLE 74 VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 75 NORTH AMERICA: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 LATIN AMERICA: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.2 VECTOR RECOVERY/HARVESTING
      • 8.2.2.1 Rising clinical trials and approvals of cell and gene-based therapies to drive demand for vector recovery/harvesting
    • TABLE 79 VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 80 NORTH AMERICA: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 EUROPE: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 LATIN AMERICA: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 DOWNSTREAM MANUFACTURING
    • TABLE 84 VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 85 VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY REGION 2021-2028 (USD MILLION)
    • TABLE 86 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 87 EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 88 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.3.1 PURIFICATION
      • 8.3.1.1 Technological advancements in purification to drive market
    • TABLE 90 PURIFICATION PROCESSES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 91 NORTH AMERICA: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 92 EUROPE: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 LATIN AMERICA: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.3.2 FILL-FINISH
      • 8.3.2.1 Technological advancements in downstream manufacturing process
    • TABLE 95 FILL-FINISH PROCESSES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 96 NORTH AMERICA: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 97 EUROPE: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 98 ASIA PACIFIC: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 LATIN AMERICA: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

9 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 100 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 CELL & GENE THERAPY
    • 9.2.1 ROBUST PIPELINE FOR CELL & GENE THERAPY TO DRIVE MARKET
    • TABLE 101 NUMBER OF CELL AND GENE THERAPIES IN CLINICAL TRIAL PHASES (2021)
    • TABLE 102 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 103 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 104 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 VACCINE DEVELOPMENT
    • 9.3.1 DEVELOPMENT OF NOVEL VACCINES TO DRIVE DEMAND FOR VIRAL VECTORS AND PLASMID DNA
    • TABLE 107 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY REGION 2021-2028 (USD MILLION)
    • TABLE 108 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 109 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 RESEARCH
    • 9.4.1 RISING R&D TO INTRODUCE NEW APPLICATIONS OF VIRAL VECTOR AND PLASMID DNA
    • TABLE 112 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY REGION 2021-2028 (USD MILLION)
    • TABLE 113 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 114 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 115 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 116 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)

10 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION

  • 10.1 INTRODUCTION
    • TABLE 117 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
  • 10.2 CANCER
    • 10.2.1 INCREASING PATIENT POPULATION TO PROPEL MARKET GROWTH
    • TABLE 118 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
    • TABLE 119 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 120 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 121 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 123 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 GENETIC DISORDERS
    • 10.3.1 LAUNCH OF ADVANCED TOOLS TO DELIVER THERAPEUTIC GENES TO SUPPORT MARKET GROWTH
    • TABLE 124 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 125 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 126 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 127 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 128 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 INFECTIOUS DISEASES
    • 10.4.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    • TABLE 129 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 133 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.5 OTHER DISEASE INDICATIONS
    • TABLE 134 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 135 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 138 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

11 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 139 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 11.2.1 GROWING CELL & GENE THERAPY R&D TO BOOST GROWTH
    • TABLE 140 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 141 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 142 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 143 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 144 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
    • 11.3.1 INCREASING DRUG DISCOVERY RESEARCH PROGRAMS TO DRIVE MARKET
    • TABLE 145 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 146 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 147 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 148 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 149 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.4 OTHER END USERS
    • TABLE 150 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 151 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 152 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 153 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 154 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

12 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 155 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 12.2 NORTH AMERICA
    • 12.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 30 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SNAPSHOT
    • TABLE 156 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 157 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 NORTH AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 160 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 161 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 162 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 163 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 164 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 165 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.2 US
      • 12.2.2.1 Increasing incidence of cancer to propel market
    • TABLE 166 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 167 US: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 169 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 170 US: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 171 US: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 172 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 173 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 174 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.3 CANADA
      • 12.2.3.1 Government initiatives to promote research to support market growth
    • TABLE 175 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 176 CANADA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 177 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 178 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 179 CANADA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 180 CANADA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 181 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 182 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 183 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3 EUROPE
    • 12.3.1 EUROPE: RECESSION IMPACT
    • TABLE 184 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 185 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 187 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 188 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 189 EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 190 EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 191 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 192 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 193 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.2 GERMANY
      • 12.3.2.1 Presence of large number of academic research institutes to propel market
    • TABLE 194 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 195 GERMANY: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 196 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 197 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 198 GERMANY: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 199 GERMANY: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 200 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 201 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 202 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.3 UK
      • 12.3.3.1 Increasing R&D investments by pharmaceutical companies to support market
    • TABLE 203 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 204 UK: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 205 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 206 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 207 UK: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 208 UK: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 209 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 210 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 211 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.4 FRANCE
      • 12.3.4.1 Focus on increasing use of generic drugs to drive market
    • TABLE 212 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 213 FRANCE: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 214 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 215 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 216 FRANCE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 217 FRANCE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 218 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 219 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 220 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.5 ITALY
      • 12.3.5.1 Collaborative research initiatives to support market growth
    • TABLE 221 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 222 ITALY: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 223 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 224 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 225 ITALY: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 226 ITALY: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 227 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 228 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 229 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.6 SPAIN
      • 12.3.6.1 Rising R&D expenditure to boost market growth
    • TABLE 230 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 231 SPAIN: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 232 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 233 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 234 SPAIN: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 235 SPAIN: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 236 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 237 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 238 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.7 REST OF EUROPE
    • TABLE 239 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 240 REST OF EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 241 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 242 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 243 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 244 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 245 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 246 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 247 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4 ASIA PACIFIC
    • 12.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 248 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 249 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 250 ASIA PACIFIC: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 251 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 252 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 253 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 254 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 255 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 256 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 257 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.2 CHINA
      • 12.4.2.1 Low manufacturing costs and high demand for medicines to drive market
    • TABLE 258 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 259 CHINA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 260 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 261 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 262 CHINA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 263 CHINA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 264 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 265 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 266 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.3 JAPAN
      • 12.4.3.1 Growing geriatric population to support market growth
    • TABLE 267 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 268 JAPAN: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 269 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 270 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 271 JAPAN: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 272 JAPAN: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 273 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 274 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 275 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.4 INDIA
      • 12.4.4.1 Growing pharmaceutical industry to create favorable opportunities for market players
    • TABLE 276 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 277 INDIA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 278 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 279 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 280 INDIA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 281 INDIA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 282 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 283 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 284 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Strong foundation for development and production of viral vectors to support market growth
    • TABLE 285 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 286 SOUTH KOREA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 287 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 288 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 289 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, 2021-2028 (USD MILLION)
    • TABLE 290 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 291 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 292 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 293 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.6 REST OF ASIA PACIFIC
    • TABLE 294 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 295 REST OF ASIA PACIFIC: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 296 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 297 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 298 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 299 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 300 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 301 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 302 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.5 LATIN AMERICA
    • 12.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 303 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 304 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 305 LATIN AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 306 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 307 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 308 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 309 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 310 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 311 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 312 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.2 BRAZIL
      • 12.5.2.1 Increasing pharmaceutical R&D to drive market
    • TABLE 313 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 314 BRAZIL: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 315 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 316 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 317 BRAZIL: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 318 BRAZIL: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 319 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 320 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 321 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.3 REST OF LATIN AMERICA
    • TABLE 322 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 323 REST OF LATIN AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 324 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 325 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 326 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 327 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 328 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 329 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 330 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET
    • 12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 331 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 332 MIDDLE EAST & AFRICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 333 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 334 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
    • TABLE 335 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 336 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 337 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 338 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021-2028 (USD MILLION)
    • TABLE 339 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021-2028 (USD MILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 31 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS, 2020-2023
  • 13.3 MARKET SHARE ANALYSIS
    • FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
    • TABLE 340 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DEGREE OF COMPETITION
  • 13.4 REVENUE SHARE ANALYSIS
    • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • FIGURE 34 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
  • 13.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
    • 13.6.1 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 341 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET
    • 13.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 342 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET
  • 13.7 COMPANY EVALUATION MATRIX: START-UPS/SMES
    • FIGURE 35 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
    • 13.7.1 PROGRESSIVE COMPANIES
    • 13.7.2 STARTING BLOCKS
    • 13.7.3 RESPONSIVE COMPANIES
    • 13.7.4 DYNAMIC COMPANIES
  • 13.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    • TABLE 343 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 344 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • 13.9 COMPETITIVE SCENARIO AND TRENDS
    • 13.9.1 PRODUCT & SERVICE LAUNCHES
    • TABLE 345 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020-MAY 2023
    • 13.9.2 DEALS
    • TABLE 346 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DEALS, JANUARY 2020-MAY 2023
    • 13.9.3 OTHER DEVELOPMENTS
    • TABLE 347 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020-MAY 2023

14 COMPANY PROFILES

  • (Business Overview, Products & services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 14.1 KEY COMPANIES
    • 14.1.1 LONZA GROUP
    • TABLE 348 LONZA GROUP: BUSINESS OVERVIEW
    • FIGURE 36 LONZA GROUP: COMPANY SNAPSHOT (2022)
    • 14.1.2 MERCK KGAA
    • TABLE 349 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 14.1.3 THERMO FISHER SCIENTIFIC INC.
    • TABLE 350 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 14.1.4 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • TABLE 351 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
    • FIGURE 39 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
    • 14.1.5 CATALENT, INC.
    • TABLE 352 CATALENT, INC: BUSINESS OVERVIEW
    • FIGURE 40 CATALENT, INC: COMPANY SNAPSHOT (2022)
    • 14.1.6 WUXI APPTEC CO., LTD.
    • TABLE 353 WUXI APPTEC CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 41 WUXI APPTEC CO., LTD.: COMPANY SNAPSHOT (2022)
    • 14.1.7 FUJIFILM CORPORATION
    • TABLE 354 FUJIFILM CORPORATION: BUSINESS OVERVIEW
    • FIGURE 42 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2022)
    • 14.1.8 GENSCRIPT BIOTECH CORPORATION
    • TABLE 355 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
    • FIGURE 43 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021)
    • 14.1.9 TAKARA BIO INC.
    • TABLE 356 TAKARA BIO INC.: BUSINESS OVERVIEW
    • FIGURE 44 TAKARA BIO INC.: COMPANY SNAPSHOT (2022)
    • 14.1.10 OXFORD BIOMEDICA
    • TABLE 357 OXFORD BIOMEDICA: BUSINESS OVERVIEW
    • FIGURE 45 OXFORD BIOMEDICA: COMPANY SNAPSHOT (2022)
    • 14.1.11 NOVARTIS AG
    • TABLE 358 NOVARTIS AG: BUSINESS OVERVIEW
    • FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2022)
    • 14.1.12 PRECISION BIOSCIENCES
    • TABLE 359 PRECISION BIOSCIENCES: BUSINESS OVERVIEW
    • FIGURE 47 PRECISION BIOSCIENCES: COMPANY SNAPSHOT (2022)
    • 14.1.13 BLUEBIRD BIO, INC.
    • TABLE 360 BLUEBIRD BIO, INC.: BUSINESS OVERVIEW
    • FIGURE 48 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)
    • 14.1.14 SARTORIUS AG
    • TABLE 361 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 49 SARTORIUS AG: COMPANY SNAPSHOT (2022)
    • 14.1.15 DANAHER CORPORATION
    • TABLE 362 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 50 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 14.1.16 SIRION BIOTECH
    • TABLE 363 SIRION BIOTECH: BUSINESS OVERVIEW
  • 14.2 OTHER PLAYERS
    • 14.2.1 VGXI, INC.
    • 14.2.2 WAISMAN BIOMANUFACTURING
    • 14.2.3 KANEKA EUROGENTEC S.A.
    • 14.2.4 PLASMIDFACTORY GMBH
    • 14.2.5 ATUM
    • 14.2.6 ADDGENE
    • 14.2.7 CELL AND GENE THERAPY CATAPULT
    • 14.2.8 BATAVIA BIOSCIENCES B.V.
    • 14.2.9 ALTOGEN BIOSYSTEMS
  • *Details on Business Overview, Products & services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS